About
Dual-drug ADCs
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyBoston & New England
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
178
By Phase
PHASE1: 1PHASE1/PHASE2: 2
By Status
COMPLETED: 2RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT04987112Lead Sponsor
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
PHASE1Recruiting
36 participants
Started: Jan 20, 2022 · Completed: Dec 30, 2024
NCT03076320Collaborator
Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne
PHASE1/PHASE2Completed
82 participants
Started: Mar 27, 2017 · Completed: Mar 31, 2019
NCT02632877Collaborator
Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers
PHASE1/PHASE2Completed
60 participants
Started: Jan 31, 2014 · Completed: Dec 31, 2015
Locations (1)
Headquarters
Woburn, MA, United States
Map
Loading map...